PE20081440A1 - Derivados de piridina como antagonistas de receptores de prostaglandinas ep1 - Google Patents

Derivados de piridina como antagonistas de receptores de prostaglandinas ep1

Info

Publication number
PE20081440A1
PE20081440A1 PE2008001431A PE2008001431A PE20081440A1 PE 20081440 A1 PE20081440 A1 PE 20081440A1 PE 2008001431 A PE2008001431 A PE 2008001431A PE 2008001431 A PE2008001431 A PE 2008001431A PE 20081440 A1 PE20081440 A1 PE 20081440A1
Authority
PE
Peru
Prior art keywords
methyl
chloro
alkyl
oxy
phenyl
Prior art date
Application number
PE2008001431A
Other languages
English (en)
Inventor
Gerad Martin Paul Giblin
Adrin Hall
David Nigel Hurst
Derek Anthony Rawlings
Tiziana Scoccitti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35735391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081440(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0428263A external-priority patent/GB0428263D0/en
Priority claimed from GB0508458A external-priority patent/GB0508458D0/en
Priority claimed from GB0524675A external-priority patent/GB0524675D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20081440A1 publication Critical patent/PE20081440A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE PIRIDINA DE FORMULA (I), DONDE X ES N Y Y ES CH, O X ES CH E Y ES N; Z ES O, S, SO O SO2; R1 ES CO2H, CH2CO2H, TETRAZOL, ENTRE OTROS; R2a Y R2b SON H, HALO, CN, NO2, ENTRE OTROS; R3a Y R3b SON H, HALO, ALQUILO C1-C8, ENTRE OTROS; Rx ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R8 ES H, FLUOR O ALQUILO; R9 ES H, HIDROXI, FLUOR, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 6-[(5-CLORO-2-{[(4-CLORO-2-FLUOROFENIL)METIL]OXI}FENIL)METIL]-2-PIRIDINCARBOXILICO, ACIDO 6-({5-CLORO-2-[(2-METIL-2-PROPEN-1-IL)OXI]FENIL}METIL)-2-PIRIDINCARBOXILICO, 6-[(5-CLORO-2-{[(2,4-DIFLUOROFENIL)METIL]OXI}FENIL)METIL]-2-PIRIDINCARBOXILATO DE SODIO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR EP1 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LAS PROSTAGLANDINAS PGE2 TALES COMO DOLOR AGUDO Y CRONICO, DOLOR NEUROPATICO, DOLOR ARTICULAR CRONICO, ENTRE OTROS
PE2008001431A 2004-12-23 2006-01-30 Derivados de piridina como antagonistas de receptores de prostaglandinas ep1 PE20081440A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds
GB0508458A GB0508458D0 (en) 2005-04-26 2005-04-26 Compounds
GB0524675A GB0524675D0 (en) 2005-12-02 2005-12-02 Compounds

Publications (1)

Publication Number Publication Date
PE20081440A1 true PE20081440A1 (es) 2008-12-31

Family

ID=35735391

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006000025A PE20060838A1 (es) 2004-12-23 2006-01-03 Acido 6- [(5 - cloro - 2-{[(4-cloro-2-fluorofenil) metil] oxi} fenil) metil]-2-acido piridincarboxilico, sales de el, asi como composiciones que lo comprenden
PE2008001431A PE20081440A1 (es) 2004-12-23 2006-01-30 Derivados de piridina como antagonistas de receptores de prostaglandinas ep1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006000025A PE20060838A1 (es) 2004-12-23 2006-01-03 Acido 6- [(5 - cloro - 2-{[(4-cloro-2-fluorofenil) metil] oxi} fenil) metil]-2-acido piridincarboxilico, sales de el, asi como composiciones que lo comprenden

Country Status (20)

Country Link
US (2) US20100137378A1 (es)
EP (2) EP1833795B1 (es)
JP (1) JP2008525363A (es)
KR (1) KR20070091301A (es)
AR (1) AR052429A1 (es)
AT (1) ATE424386T1 (es)
AU (1) AU2005318372A1 (es)
BR (1) BRPI0519398A2 (es)
CA (1) CA2592442A1 (es)
DE (1) DE602005013116D1 (es)
EA (2) EA200701324A1 (es)
ES (1) ES2321535T3 (es)
IL (1) IL183781A0 (es)
MA (1) MA29082B1 (es)
MX (1) MX2007007830A (es)
NO (1) NO20073332L (es)
PE (2) PE20060838A1 (es)
TW (1) TW200640865A (es)
UY (1) UY29298A1 (es)
WO (1) WO2006066968A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0608825D0 (en) * 2006-05-04 2006-06-14 Glaxo Group Ltd Compounds
CA2687764A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
EP2421835A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
SG178252A1 (en) 2009-08-05 2012-03-29 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
TWI675827B (zh) 2014-06-03 2019-11-01 瑞士商愛杜西亞製藥有限公司 吡唑化合物
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
WO2017173274A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
BR112019011208A2 (pt) 2016-12-16 2019-10-15 Idorsia Pharmaceuticals Ltd combinação farmacêutica, composição farmacêutica, e, kit de partes.
JP6972144B2 (ja) 2017-02-06 2021-11-24 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd １−アリール−１−トリフルオロメチルシクロプロパンを合成するための新規な方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MX2020001302A (es) 2017-08-02 2020-03-20 Vertex Pharma Procesos para preparar compuestos de pirrolidina.
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1471276A (en) 1975-01-22 1977-04-21 Nippon Shinyaku Co Ltd 5-benzylpicolinic acid deri vatives
EP0388682A1 (de) 1989-03-15 1990-09-26 Bayer Ag Substituierte Heteroarylphenylether, Verfahren zu ihrer Herstellung und ihre Verwendung als Insektizide
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
EP0738144A4 (en) 1993-12-30 1999-06-30 Smithkline Beecham Corp PHENYLMETHYL HEXANAMIDES AND THEIR USE
GB9514160D0 (en) 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
ES2183935T3 (es) 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
DE69635254T2 (de) 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
CN1098256C (zh) 1996-04-12 2003-01-08 G·D·瑟尔公司 作为cox－2抑制剂前药的取代的苯磺酰胺衍生物
EE03680B1 (et) 1996-07-18 2002-04-15 Merck Frosst Canada & Co. / Merck Frosst Canada &Cie. Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
YU11900A (sh) 1997-09-05 2002-11-15 Glaxo Group Limited Derivati 2,3-diaril-pirazolo (1,5-b) piridazina, njihovo dobijanje i njihova upotreba kao inhibitora ciklooksigenaze 2(cox-2)
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
AU3285499A (en) 1998-02-13 1999-08-30 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
ES2228127T3 (es) 1998-11-03 2005-04-01 Glaxo Group Limited Derivados de pirazolopiridina como inhibidores selectivos de cox-2.
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
US6498166B1 (en) 1999-02-27 2002-12-24 Smithkline Beecham Corporation Pyrazolopyridines
ES2213601T3 (es) 1999-09-14 2004-09-01 MERCK FROSST CANADA & CO. Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimiento de tratamiento.
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
JP2005522477A (ja) 2002-04-08 2005-07-28 グラクソ　グループ　リミテッド （２−（（２−アルコキシ）−フェニル）−シクロペント−１−エニル）芳香族炭素環式および複素環式酸および誘導体
GB0212785D0 (en) 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
KR20050084890A (ko) 2002-10-30 2005-08-29 머크 프로스트 캐나다 앤드 캄파니 피리도피롤리진 및 피리도인돌리진 유도체
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
GB0306329D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0323585D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
GB0323584D0 (en) 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
JP2007509104A (ja) 2003-10-24 2007-04-12 グラクソ　グループ　リミテッド 複素環式化合物
GB0328024D0 (en) 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
GB0410121D0 (en) 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EP2053042A1 (en) 2009-04-29
JP2008525363A (ja) 2008-07-17
IL183781A0 (en) 2007-09-20
EP1833795B1 (en) 2009-03-04
EA200701324A1 (ru) 2007-10-26
UY29298A1 (es) 2006-05-31
MA29082B1 (fr) 2007-12-03
EA200801909A1 (ru) 2009-06-30
BRPI0519398A2 (pt) 2009-01-20
EP1833795A1 (en) 2007-09-19
KR20070091301A (ko) 2007-09-10
US20080249138A1 (en) 2008-10-09
AR052429A1 (es) 2007-03-21
US20100137378A1 (en) 2010-06-03
CA2592442A1 (en) 2006-06-29
US7759369B2 (en) 2010-07-20
DE602005013116D1 (de) 2009-04-16
ATE424386T1 (de) 2009-03-15
PE20060838A1 (es) 2006-10-12
NO20073332L (no) 2007-09-17
WO2006066968A1 (en) 2006-06-29
TW200640865A (en) 2006-12-01
ES2321535T3 (es) 2009-06-08
AU2005318372A1 (en) 2006-06-29
MX2007007830A (es) 2007-07-25

Similar Documents

Publication Publication Date Title
PE20081440A1 (es) Derivados de piridina como antagonistas de receptores de prostaglandinas ep1
PE20091014A1 (es) Compuestos espiro y uso farmaceutico de los mismos
US20060135572A1 (en) CaSR antagonist
SE0200979D0 (sv) New compounds
EA201200763A1 (ru) Замещенные производные карбамоилметиламиноуксусной кислоты в качестве новых ингибиторов nep
PE20090695A1 (es) Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
BR0207910A (pt) HidantÈnios e sua utilização no tratamento do diabetes
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
GT200500156A (es) Derivados de acido carboxilico de bencimidazolona
HRP20020404B1 (en) Solutions containing epinastine
US20150352094A1 (en) Use of fatty acid niacin conjugates for treating diseases
PE20130210A1 (es) Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
SE0100569D0 (sv) New compounds
EA201000120A1 (ru) Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
RU2011121809A (ru) Производное циклогексана и его фармацевтическое применение
RU2008142831A (ru) Производные бензимидазола
PE20060001A1 (es) COMPUESTOS DE ß-CETOAMIDA COMO ANTAGONISTAS DE MCH
CO5611150A2 (es) Formulacion en aerosol de una sal de tiotropio de administracion directa para inhalacion
SE0401655D0 (sv) New compounds
AR044014A1 (es) Composiciones farmaceuticas para administracion intranasal de acido [2-(8,9-dioxo-2, 6-diazabiciclo [5.2.0) non-1 (7) -en-2-il)alquil]-fosfonico y derivados y metodos de utilizacion de las mismas
PT1412332E (pt) Derivados de quinolina e sua utilizacao como agentes antitumorais
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
AR067047A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal